Antisense oligonucleotides targeted against human immunodeficiency virus

• US 5,811,537 A
• Filed: 01/14/1997
• Issued: 09/22/1998
• Est. Priority Date: 06/23/1993
• Status: Expired due to Fees

• Current Assignee: Novopharm Biotech, Inc.
• Original Assignee: Novopharm Biotech, Inc.
• Inventors: Friesen, Albert D.
• Primary Examiner(s): LeGuyader, John L.
• Application Number:
  US08/782,980
• Time in Patent Office: 616 Days
• Field of Search: 435/6, 435/91.1, 435/172.1, 435/172.3, 435/320.1, 435/325, 435/366, 514/44, 536/23.1, 536/24.1, 536/24.5
• US Class Current: 536/24.5
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C12N 15/1132 against retroviridae, e.g. HIV
• CPC Class Codes: C12N 2310/315 Phosphorothioates

Abstract

The present invention is directed to oligonucleotides comprising nucleotide sequences sufficiently complementary to conserved regions of human immunodeficiency virus genetic material such that when bound to said region, the oligonucleotides effectively prevent expression of the genetic material.

Claims

1. An oligonucleotide having a nucleotide sequence complementary to a nucleic acid sequence selected from the group consisting of:

+5399 to +5418; and

+5552 to +5566 of human immunodeficiency virus.

4. A composition comprising an oligonucleotide according to claim 1 and a pharmaceutically acceptable carrier therefor.

2. An oligonucleotide having the nucleotide sequence selected from the group consisting of:

5'"'"' GGCTCCATTTCTTGCTCTCC 3'"'"' (SEQ ID NO;

     2); and

5'"'"' CCGCTTCTTCCTGCC 3'"'"' (SEQ ID NO;

     3).

5. A composition comprising an oligonucleotide according to claim 2 and a pharmaceutically acceptable carrier therefor.

3. An oligonucleotide having the nucleotide sequence selected from the group consisting of:

5'"'"'G^s GC^s TC^s CA^s TTTC^s TTG^s CTC^s TC^s C 3'"'"'(SEQ ID NO;

     5); and

5'"'"' C^s CG^s C^s TTCTTC^s C^s TGC^s C3'"'"' (SEQ ID NO;

6;

wherein s stands for a sulfur atom.

6. A composition comprising an oligonucleotide according to claim 3 and a pharmaceutically acceptable carrier therefor.